By Cory Doctorow | BoingBoing | July 27, 2017 It’s been years since the major pharma companies agreed to participate in the Registry of All Trials, meaning that they’d end the practice of only reporting on trials whose outcomes they were pleased with, leaving about half of all trials unreported-on. Today, Ben Goldacre (who is […]
Source